R

ise and shine, everyone. The middle of the week is upon us. Have heart, though. You made it this far, so why not hang on for another couple of days, yes? And what better way to make the time fly than to keep busy. So grab that cup of stimulation — our flavor today boasts the aroma of blueberries — and get started. Meanwhile, we are happy to pass along the latest menu of tidbits to help you on your way. Hope you have a productive day and do stay in touch. We accept documents and tips …

Celgene (CELG) admitted bungling an attempt to win approval for an important new drug in a “self-inflicted” error that damaged its credibility on Wall Street, The Financial Times says. Earlier this year, the Food and Drug Administration refused to review an application for a multiple sclerosis pill because Celgene had not done enough work to understand how the drug was metabolized. “[The FDA] kinda said ‘What happened, guys, this isn’t what we usually expect from Celgene?’ And we had to say, you know, ‘mea culpa. It’s on us’,” says Nadim Ahmed, who heads hematology and oncology at Celgene.

Unlock this article by subscribing to STAT Plus. Try it FREE for 30 days!

SUBSCRIBE TODAY

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.

Privacy Policy